Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results

To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment. Multicenter, randomized clinical trial. Patients (n = 1107) who were followed up during year 2 among...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Ophthalmology (Rochester, Minn.) Ročník 127; číslo 4S; s. S135
Hlavní autori:	Martin, Daniel F, Maguire, Maureen G, Fine, Stuart L, Ying, Gui-Shuang, Jaffe, Glenn J, Grunwald, Juan E, Toth, Cynthia, Redford, Maryann, Ferris, 3rd, Frederick L
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.04.2020
Predmet:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Bevacizumab - therapeutic use Choroidal Neovascularization - diagnosis Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology Female Fluorescein Angiography Humans Intravitreal Injections Male Middle Aged Ranibizumab - therapeutic use Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
ISSN:	1549-4713, 1549-4713
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!